Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care.
We begin with an editorial from Marcio José Concepción-Zavaleta and colleagues, who explore the limitations of conventional metabolic syndrome criteria in older adults. The authors argue for a shift from rigid diagnostic thresholds toward functional, frailty-based assessments that better capture metabolic health in ageing populations.
In the field of diabetes, Jennifer Clements and co-authors provide a timely overview of continuous glucose monitoring in hospital settings. Their article discusses the clinical benefits, practical challenges and future potential of this technology to improve glycaemic control and patient outcomes during hospitalization.
Taieb Ach et al. examine polycystic ovary syndrome through a multidisciplinary lens, advocating for the integration of metabolic health into gynaecologic and dermatologic care. Their editorial highlights how emerging therapies, including sodium–glucose cotransporter-2 inhibitors, are fostering a more holistic approach to management.
Turning to thyroid disorders, Seyed Omid Mohammadi and Coby Ray discuss the evolving treatment landscape for thyroid eye disease. Their article outlines the role of biologic therapies, such as teprotumumab, in improving outcomes and quality of life for patients with this autoimmune condition.
The issue also includes an important review from Simran Thakkar and colleagues exploring the potential long-term effects of foetal exposure to metformin. The authors assess current evidence linking in utero exposure to altered adiposity and cardiovascular risk in childhood, underscoring the need for precision-medicine approaches to guide treatment during pregnancy.
In the area of metabolic liver disease, Burhan Gunawan et al. present a systematic review and meta-analysis comparing dual and single incretin receptor agonists in individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Their findings support dual receptor agonists as promising agents for improving liver fibrosis and reducing fat content.
This issue also features original research from Subhankar Chatterjee and colleagues, who investigate the relationship between anthropometric measures and cognitive function in patients with type 2 diabetes. Their findings suggest that lean individuals may be at greater risk of cognitive impairment, offering new insight into the metabolic–neurological connection.
We would like to thank all those who contributed the insightful and informative articles included in this edition. A special thanks also goes to our editorial board for their continuing support and guidance. We are also grateful to all organizations and media partners for their ongoing support. We hope that you find these topical articles interesting and informative.
John Doupis
Dr John Doupis is a former clinical research fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA and scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. Currently, he is directing the Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center in Athens, Greece. He has served as a principal investigator in many multicentre phase I, II, III and IV clinical trials, most of which have been published in international journals or presented at congresses. He is a registered reviewer and a member of the editorial board for many major diabetes medical journals. He has given numerous lectures in national and international congresses, presenting over 200 abstracts. His special areas of interest are diabetes and its complications, especially obesity, diabetic neuropathy, diabetic foot, as well as the glucose sensing technologies and insulin pumps. In these fields, he has published more than 50 papers in international medical journals, having more than 1,500 citations.
